Alpha DNA Investment Management LLC purchased a new position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 33,552 shares of the biopharmaceutical company’s stock, valued at approximately $1,081,000. Other hedge funds […]
Insider Selling: Revance Therapeutics, Inc. (NASDAQ:RVNC) CEO Sells 26,279 Shares of Stock theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Brokerages Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $42.55 kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Essex Investment Management Co. LLC increased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 59.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,613 shares of the biopharmaceutical company’s stock after acquiring an […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) CEO Mark J. Foley sold 26,279 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $24.94, for a total transaction of $655,398.26. Following the transaction, the chief executive officer now directly owns 866,654 shares of the […]